glp 1 in non diabetic The cardiovascular effects of GLP-1 receptor agonists beyond obesity and type 2 diabetes: An anti-atherosclerotic action GLP-1 for Weight Loss and
Description
2003;284:R1427R1435
The disease spectrum of MASLD ranges from benign hepatic steatosis to more severe forms, including metabolic steatohepatitis (MASH), which can progress to liver fibrosis, cirrhosis, and ultimately, liver failure
Journal reference: Tejeji I., Zeier T., Smith J
Executive Director Shabbir Safdar joined the editorial board of the Journal of Illicit Trade, Financial Crime, and Compliance
Metabolic Lab Testing Comprehensive bloodwork every six months
doi: 10.1038/s41598-023-47217-2
